FDA tells ImmunoGen to run a second phase 3, sinking stock

The FDA has quashed ImmunoGen’s hopes of filing for approval of mirvetuximab soravtansine on the strength of a failed phase 3 trial. FDA officials advised ImmunoGen a run a new phase 3 in patients with high folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer before seeking approval.